Details for Patent: 4,584,305
Summary for Patent: 4,584,305
| Title: | Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole |
| Abstract: | Process of aiding regression and palliation of neoplastic disease in animal and human hosts comprising systemic administration to phenylimidazo[2,1-b]thiazole or a nontoxic acid addition salt thereof. Preferably the active ingredient is administered in a sufficient amount to provide dosages over the range from about 1 mg to about 5 mg/kg of body weight of the host. |
| Inventor(s): | Josephus Brugmans, William Pollack, Paul A. J. Janssen, Daniel Tripodi |
| Assignee: | Janssen Pharmaceutica NV |
| Application Number: | US06/230,578 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Process; |
Drugs Protected by US Patent 4,584,305
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 4,584,305
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 5910573 | ⤷ Start Trial | |||
| Belgium | 803718 | ⤷ Start Trial | |||
| Germany | 2340632 | ⤷ Start Trial | |||
| France | 2196172 | ⤷ Start Trial | |||
| Philippines | 9277 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
